L3VLUP
ProSign in

TNGX · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TNGXJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TNGX
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterTNGXJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 2021none listed holders, n.a.31 holders, $25.3bn
Q2 2021none listed holders, n.a.37 holders, $25.6bn
Q3 20212 holders, $10m40 holders, $24.1bn
Q4 20212 holders, $8.8m33 holders, $25.2bn
Q1 20222 holders, $6.1m35 holders, $28.2bn
Q2 20222 holders, $3.6m33 holders, $26.9bn
Q3 20222 holders, $2.9m36 holders, $25.4bn
Q4 20222 holders, $4.6m35 holders, $27.6bn
Q1 20231 holders, $1.4m42 holders, $24.5bn
Q2 20231 holders, $875k38 holders, $25.0bn
Q3 20231 holders, $2.8m37 holders, $18.9bn
Q4 2023none listed holders, n.a.31 holders, $19.0bn
Q1 2024none listed holders, n.a.32 holders, $19.7bn
Q2 20241 holders, $3.0m35 holders, $20.4bn
Q3 2024none listed holders, n.a.28 holders, $22.3bn
Q4 20241 holders, $12m37 holders, $20.4bn
Q1 20251 holders, $6.3m32 holders, $20.5bn
Q2 20252 holders, $78m31 holders, $18.4bn
Q3 20253 holders, $166m32 holders, $23.7bn
Q4 20253 holders, $252m29 holders, $27.8bn
Q1 20265 holders, $570m34 holders, $35.6bn
Q2 20265 holders, $805m33 holders, $39.1bn
TNGX

Tango Therapeutics Inc

Holders
3
Reported value
$252m
Buyers
14
Sellers
10

Breadth +4 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TNGX (2)

Balyasny Asset Management LLC, Farallon Capital Management LLC

Only JNJ (28)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, and 3 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →